IMAGINATOR 2.0: Co-design and Early Evaluation of a Novel Blended Digital Intervention Targeting Self-harm in Young People
Launched by IMPERIAL COLLEGE LONDON · Mar 7, 2024
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
An open single-arm study that investigates the IMAGINATOR intervention comprising of delivery of Functional Imagery Training (FIT) for self-harm supported by a new co-designed smartphone app for young people aged 12-25 who experience current repeated self-harming behaviour and have been referred to adult community mental health services (Mental Health Integrated Network Teams; MINT) or Community Child and Adolescent Mental Health Services (CAMHS).
For the purpose of this study, self-harm is defined as per NICE guidelines (NICE, 2012): "an act of self-poisoning or self-injury, irrespective ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 12 - 25 years old
- • 2. Presented with at least 2 episodes of self-harm lifetime, with at least 1 of these in the past month or 5 episodes of self-harm in the past year (based on NSSI Disorder criteria in the DSM-5) and currently reporting self-harm urges or difficulties stopping
- • 3. Have a smartphone
- • 4. Can commit to attending 3 consecutive weekly FIT sessions, and 5 follow-up telephone sessions, and assessments over follow up period as required by the study
- • 5. Have adequate English language ability to permit the assessment and experimental measures to be completed, and use the smartphone app
- • 6. Willing to consent to receive support to reduce / improve management of self-harm urges and behaviour; in person or by video, and over the phone and via smartphone app
- • 7. If 12 - 15 years old, willing for parent/guardian to provide consent to study participation
- • 8. Willing to have letters sent/phone calls made to their GP and other relevant clinicians
- • 9. Resident within geographical areas covered by the West London NHS Trust CCAMHS and MINT teams.
- Exclusion Criteria:
- The participant may not enter the study if any of the following apply:
- • 1. Severe learning disability or pervasive developmental disorder
- • 2. Current acute psychotic episode
- • 3. Current substance dependence
- • 4. Imminent risk of suicide or harm to others (based on clinicians' risk assessment, see Section 4.1)
- • 5. Insufficient English language fluency to complete study outcome measures
- • 6. Taking part in concurrent treatment studies investigating pharmacological or psychological treatment for self-harm
- • 7. Unwilling to engage actively in the FIT intervention or to use an imagery-focused approach for treatment
- • 8. Unwilling to use a smartphone app.
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported